Luca Benatti

Dr. Benatti has over 30 years of experience in the pharmaceutical and biotechnology industries. He serves as the Chief Executive Officer and a Director of EryDel S.p.A., a private biotechnology company focused on rare diseases.

Prior to EryDel, Dr. Benatti was Co-founder and CEO of Newron Pharmaceuticals S.p.A. Under his leadership, Newron developed a pipeline of innovative therapies including Xadago, approved worldwide for the treatment of Parkinson's Disease. Previously, Dr. Benatti held research and development positions at Pharmacia & Upjohn and its predecessor companies. Dr. Benatti has authored several scientific publications and holds a number of patents.

He currently serves as a director of Intercept Pharmaceuticals, Newron Pharmaceuticals S.p.A., and Metis Precision Medicine. Dr. Benatti also serves as chairman of Italian Angels for Biotech, a member of the Advisory Board of the Sofinnova Telethon Fund, and as a member of the Development and of the Strategic Advisory Boards of Zambon S.p.A. Dr. Benatti graduated and performed post-doctoral work at the Milano Genetics Institute.